Clinical Study on the Treatment of Postpartum Anemia With Compound E Jiao Jiang(cEJJ）

Inclusion criteria

• Patients diagnosed with mild or moderate anemia (70g/L≤Hb < 110g/L) within 1 week postpartum and suitable for oral drug therapy;
• Age 18-45 years old (including 18 and 45);
• Those who do not use other iron agents and Chinese medicine/Chinese medicine preparations that have the effect of invigorating qi and nourishing blood during the study;
• Sign the subject's informed consent voluntarily.

Exclusion criteria

• Postpartum hemorrhage and blood transfusion treatment;
• Those who received intramuscular/intravenous iron therapy or transfused blood products/human blood albumin and other plasma volume dilators within 3 months prior to screening;
• Patients who have taken blood tonics within 1 week before screening, including other iron preparations and Chinese medicine or Chinese medicine preparations;
• People with previous blood diseases such as sickle cell anemia, thalassemia, aplastic anemia, megaloblastic anemia;
• Severe preeclampsia during pregnancy;
• Abortion occurs in this pregnancy;
• Patients with a serious digestive disease, cardiovascular disease, immune system disease, or serious mental disorder that the investigator believes may adversely affect the safety of the subject and/or the effectiveness of the investigational drug;
• Severe hepatic and renal insufficiency (ALT >2×ULN, aspartate aminotransferase (AST)>2×ULN, Urea (Urea)/ urea nitrogen (BUN)>2×ULN, creatinine (Cr)>1×ULN);
• Those who have a history of alcohol abuse, drug abuse or drug use before;
• Allergic to the experimental drug or known ingredient;
• Participants who had participated in other clinical trials within 3 months before screening;
• Those who, according to the judgment of the investigator, consider it inappropriate to participate in this clinical trial.